January 1, 2025
An Imaging-related Clinical Trial Endpoint
Ellipsoid zone integrity is an OCT biomarker in dry age-related macular degeneration that the FDA now supports as an approvable clinical trial endpoint.
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/yrbnrfey/cover_july_aug25.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/0amghqej/cover_julyaug25.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/rnjiohrl/cover_june25_web.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/5isnzmog/0725-op-cover-final-1.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/upwdjelf/0725_cover_final.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/aqbjxwjw/pp-cover.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/npjdtl1w/cp_november_cover.jpg
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://www.retinalphysician.com/media/mvqdq2hc/nrp_cover_october_2024.jpg
October 18, 2024 - October 21, 2024
Chicago, Illinois
The Academy's annual meeting will take place at McCormick Place in Chicago.
January 1, 2025
Ellipsoid zone integrity is an OCT biomarker in dry age-related macular degeneration that the FDA now supports as an approvable clinical trial endpoint.
By Jim Gallagher, senior managing editor
October 25, 2024
During Retina Subspecialty Day at AAO 2024, Paul Hahn, MD, PhD, discussed recent studies that examined the financial impact of step therapy and inflation on retinal physician reimbursement. The studies were performed by the Health Economics Committee of the American Society of Retina Specialists.
By Paul Hahn, MD, PhD
October 25, 2024
Peter K. Kaiser, MD, and Diana V. Do, MD, discuss first-time results of a bilateral dosing study of subretinal ABBV-RGX-314 for wet AMD.
By Peter K. Kaiser, MD, Diana V. Do, MD
October 25, 2024
Yasha Modi, MD, discusses the 17th Charles L. Schepens Lecture given by legendary innovator and surgeon Dr. Steve Charles during Retina Subspecialty Day at AAO 2024.
By Yasha Modi, MD
October 25, 2024
Data from the SAGA study, presented at AAO, showed patients with geographic atrophy demonstrated a trend toward functional benefit in BCVA at month 24.
By Jim Gallagher, senior managing editor
October 25, 2024
Drs. Schleifer and Yancopoulos received the Eyecelerator Innovation Award and discussed the long and winding road to success.
By Jim Gallagher, senior managing editor
October 19, 2024
First-time results of a bilateral dosing study of subretinal ABBV-RGX-314 for nAMD were presented during Retinal Subspecialty Day at AAO.
By Jim Gallagher, senior managing editor
October 19, 2024
Pooled data from 3 clinical trials, presented during the AAO meeting in Chicago, indicates revakinagene taroretcel prevents deterioration of visual function.
By Jim Gallagher, senior managing editor
October 19, 2024
Yasha Modi, MD, discusses the decision-making process for surgical treatment of epiretinal membrane during Saturday's Retina Subspecialty Day at the 2024 American Academy of Ophthalmology meeting in Chicago.
By Yasha Modi, MD
October 19, 2024
Peter K. Kaiser, MD, and Diana Do, MD, discuss 3-year data from the PHOTON trial for diabetic macular edema at the 2024 American Academy of Ophthalmology meeting.
By Peter K. Kaiser, MD, Diana V. Do, MD
October 18, 2024
Evolving approaches to treatment, and advancements in identifying and treating ocular melanomas, have greatly improved patient survival rates and quality of life.
By Jim Gallagher, senior managing editor
October 18, 2024
Data from the ELEVATUM trial, presented at AAO, indicates that Hispanic and Black patients with diabetic macular edema responded well to treatment with faricimab.
By Jim Gallagher, senior managing editor
October 18, 2024
Three-year data from the GALE open-label extension study, presented at AAO, demonstrated an anatomical and visual function benefit of continuous pegcetacoplan treatment for patients with subfoveal geographic atrophy.
By Jim Gallagher, senior managing editor
October 18, 2024
The chandelier scleral buckle procedure, using radial or segmental sponge explants, offers better visualization, reducing complications and improving outcomes.
By Jim Gallagher, senior managing editor
October 18, 2024
The legendary surgeon and innovator delivered the 17th Charles Schepens Lecture during Retina Subspecialty Day on Friday morning. He spoke with Retinal Physician about this honor.
By Jim Gallagher, senior managing editor
October 18, 2024
Data from 2 pivotal trials showed that the Scanly Home OCT device offers accurate, reliable monitoring for nAMD patients between office visits.
By Jim Gallagher, senior managing editor